- Home
- PMM vs ABEO Comparison
PMM vs ABEO Comparison
Compare PMM & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- ABEO
- Stock Information
- Founded
- PMM 1989
- ABEO 1974
- Country
- PMM United States
- ABEO United States
- Employees
- PMM N/A
- ABEO N/A
- Industry
- PMM Investment Managers
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- PMM Finance
- ABEO Health Care
- Exchange
- PMM Nasdaq
- ABEO Nasdaq
- Market Cap
- PMM 265.3M
- ABEO 304.4M
- IPO Year
- PMM N/A
- ABEO 1980
- Fundamental
- Price
- PMM $5.78
- ABEO $6.84
- Analyst Decision
- PMM
- ABEO Strong Buy
- Analyst Count
- PMM 0
- ABEO 6
- Target Price
- PMM N/A
- ABEO $18.00
- AVG Volume (30 Days)
- PMM 118.3K
- ABEO 699.7K
- Earning Date
- PMM 01-01-0001
- ABEO 08-11-2025
- Dividend Yield
- PMM 4.68%
- ABEO N/A
- EPS Growth
- PMM N/A
- ABEO N/A
- EPS
- PMM 0.23
- ABEO N/A
- Revenue
- PMM N/A
- ABEO N/A
- Revenue This Year
- PMM N/A
- ABEO N/A
- Revenue Next Year
- PMM N/A
- ABEO $322.37
- P/E Ratio
- PMM $26.52
- ABEO N/A
- Revenue Growth
- PMM N/A
- ABEO N/A
- 52 Week Low
- PMM $5.00
- ABEO $3.93
- 52 Week High
- PMM $6.42
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- PMM 35.59
- ABEO 65.40
- Support Level
- PMM $5.77
- ABEO $6.36
- Resistance Level
- PMM $5.86
- ABEO $6.94
- Average True Range (ATR)
- PMM 0.05
- ABEO 0.30
- MACD
- PMM -0.01
- ABEO 0.05
- Stochastic Oscillator
- PMM 5.00
- ABEO 80.70
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.